2:28 PM
 | 
May 02, 2019
 |  BC Extra  |  Company News

May 2 Company Quick Takes: Agios, Celgene/Presage, Purdue, Amgen/Syapse

Editor's Note: This article was updated on May 02, 2019 at 3:30 PM PDT

Label expansion in AML for Agios’ Tibsovo
FDA approved an sNDA for Tibsovo ivosidenib from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) as monotherapy for adults with newly diagnosed acute myelogenous leukemia (AML) with a susceptible isocitrate dehydrogenase 1 (IDH1) mutation who are ineligible for intensive chemotherapy. The agency first approved Tibsovo in July 2018 for relapsed or refractory AML...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >